MAZE
NASDAQ
$29.30
Maze Therapeutics Inc (MAZE)
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $62.55 (+113.48%)
Market Cap
$1.46B
Free Cash Flow Yield
-8.35%
Beta (5Y)
0.87
Price Chart
Valuation
Market Cap$1.46B
Forward P/E8.53
P/S81.33
P/B4.84
Profitability
Total Revenue (TTM)$20M
Gross Profit (TTM)$20M
EBITDA-$132M
Operating Margin-132.8%
EPS-$2.58
Financial Health
Debt-to-Equity11.4%
Free Cash Flow Yield-8.35%
Growth & Risk
Beta (5Y)0.87
Sharpe Ratio0.96